-
Just! Eli Lilly Alzheimer's disease antibody therapy is proposed to be included in the breakthrough therapy variety
Time of Update: 2023-02-02
Today (January 9), the official website of the Center for Drug Evaluation (CDE) of China's National Medical Products Administration announced that Eli Lilly and Company Donanemab injection, a Class 1
-
Science sub-journal: Alzheimer's disease antibody therapy innovation! An Zhiqiang's team developed a quadrivalent TREM2 agonist antibody
Time of Update: 2022-10-03
Ab18 TVD-Ig/αTfR enhances cognitive function in AD-mode miceOverall, this study shows that through antibody engineering combined with TfR-mediated brain delivery, multivalent TREM2 agonist antibodies that can pass through the blood-brain barrier can be obtained, which strengthens microglial function, reduces Aβ pathological deposition, and promotes the development of clinically effective therapeutic measures targeting TREM2.
-
Express for the treatment of Alzheimer's disease, Genentech's anti-amyloid antibody therapy was approved by the FDA as a breakthrough therapy
Time of Update: 2021-10-22
▎The content team editor of WuXi AppTec today, Genentech, a subsidiary of Roche, announced that the US FDA has granted an anti-β-amyloid antibody therapy gantenerumab breakthrough therapy designation for the treatment of Alzheimer’s disease (AD ) .
-
Express treatment of Alzheimer's disease, Eisai/Bojian's second amyloid antibody therapy starts rolling application
Time of Update: 2021-10-10
▎Editor of WuXi AppTec's content team On September 27, Eisai and Biogen jointly announced that they have submitted a rolling submission for the treatment of early-stage Alzheimer's disease (AD) antibodies to the US FDA through the accelerated approval channel Biological product license application (BLA) for the therapy lecanemab (BAN2401) .
-
Alzheimer's disease antibody therapy application is submitted soon, Eli Lilly updates company structure
Time of Update: 2021-09-05
Patrik Jonsson will become President of Eli Lilly Immunology, responsible for the development and product launch of Eli Lilly’s dermatology, gastroenterology and rheumatology phase 3 pipelines .
Reference materials:[1] Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units.
-
Courier Advances Phase 3 Trial of Alzheimer's Disease Antibody Therapy, Eli Lilly Reaches Strategic Cooperation
Time of Update: 2021-08-07
The randomized, double-blind, placebo-controlled Phase 3 clinical trial TRAILBLAZER-ALZ 3 will evaluate the Lilly's research antibody therapy donanemab to slow Alzheimer's in patients at risk of cognitive and functional decline associated with Alzheimer's disease The possibility of clinical progression of silent disease, regardless of whether the subject carries the APOE4 gene .
-
Is the development of Alzheimer's disease therapy about to turn a corner? In-depth interpretation of Lilly in the study of antibody detailed results
Time of Update: 2021-03-21
▎The content team editor of WuXi AppTec last weekend, Eli Lilly and Company (Eli Lilly and Company) published in the "New England Journal of Medicine" the detailed results of its Phase 2 clinical trial of its Alzheimer's disease (AD) antibody therapy donanemab.
-
Lilly Alzheimer's antibody therapy reaches the main clinical endpoint of Phase 2
Time of Update: 2021-01-22
Dr. Daniel Skovronsky, Chief Scientific Officer of Lilly, Targeting Amyloid, said Donanemab's ability to quickly remove amyloid plaques and the company's expertise in amyloid and tau protein imaging technology allow researchers to detect the hypothesis that reducing amyloid plaques in Alzheimer's patients to the same levels as in healthy people can significantly delay cognitive decline.
-
J Neuroinflammation: Developed the first targeted antibody therapy that promises to be effective in treating Alzheimer's disease.
Time of Update: 2020-10-07
based on this study, the researchers found that using TREM2 to activate antibodies to therapeutically target the effect of TREM2 may activate small glial cells and recruit small glial cells into amyloid plaques to reduce amyloid plaques Accumulation, which ultimately improves the cognitive abilities of patients, and most importantly, is the first method to target TREM2 to promote the removal of amyloid plaques in the brain, which are thought to be the main cause of Alzheimer's disease.
